BR112016007627A2 - composições farmacêuticas tópicas para a pele contendo icotinib e utilizações das mesmas - Google Patents

composições farmacêuticas tópicas para a pele contendo icotinib e utilizações das mesmas

Info

Publication number
BR112016007627A2
BR112016007627A2 BR112016007627A BR112016007627A BR112016007627A2 BR 112016007627 A2 BR112016007627 A2 BR 112016007627A2 BR 112016007627 A BR112016007627 A BR 112016007627A BR 112016007627 A BR112016007627 A BR 112016007627A BR 112016007627 A2 BR112016007627 A2 BR 112016007627A2
Authority
BR
Brazil
Prior art keywords
topical
preparations
icotinib
pharmaceutical compositions
methods
Prior art date
Application number
BR112016007627A
Other languages
English (en)
Inventor
Hu Shaojing
Yuan Shujun
Wang Yanping
Wang Yinxiang
Hu Yunyan
Original Assignee
Betta Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betta Pharmaceuticals Co Ltd filed Critical Betta Pharmaceuticals Co Ltd
Publication of BR112016007627A2 publication Critical patent/BR112016007627A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

a presente invenção refere-se a preparações tópicas para inibição de tirosina quinase e métodos de preparação das mesmas, e especialmente a composições farmacêuticas tópicas para inibição de tirosina quinase e métodos de preparação das mesmas. o ingrediente ativo das preparações tópicas é icotinib ou um sal farmaceuticamente aceitável do mesmo. as preparações são adequadas para aplicação tópica, com mínima irritação da pele, sem reações adversas tais como prurido, sensações de queimação, formigamento, pele seca, eritema e rashes, sem efeitos colaterais relacionados com parahormônios tais como atrofia da pele, pigmentação ou hipopigmentação para utilização por longo prazo, bem como sem sintomas dermatológicos relacionados depois de retirada do fármaco. os métodos de preparação são facilmente entendidos, operáveis, e controláveis, e são adequados para produção industrial em massa.
BR112016007627A 2013-10-11 2014-10-11 composições farmacêuticas tópicas para a pele contendo icotinib e utilizações das mesmas BR112016007627A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2013085042 2013-10-11
PCT/CN2014/088344 WO2015051763A1 (zh) 2013-10-11 2014-10-11 一种含埃克替尼的皮肤外用药物组合物及其应用

Publications (1)

Publication Number Publication Date
BR112016007627A2 true BR112016007627A2 (pt) 2017-08-01

Family

ID=52812537

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016007627A BR112016007627A2 (pt) 2013-10-11 2014-10-11 composições farmacêuticas tópicas para a pele contendo icotinib e utilizações das mesmas

Country Status (13)

Country Link
US (2) US20160235757A1 (pt)
EP (1) EP3056206A4 (pt)
JP (1) JP6463745B2 (pt)
AU (1) AU2014334222B2 (pt)
BR (1) BR112016007627A2 (pt)
CA (1) CA2926874C (pt)
HK (1) HK1213813A1 (pt)
IL (1) IL245015A0 (pt)
NZ (1) NZ718802A (pt)
RU (1) RU2698796C2 (pt)
SG (1) SG11201602826VA (pt)
TW (1) TWI630921B (pt)
WO (1) WO2015051763A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6523259B2 (ja) * 2013-06-09 2019-05-29 ベータ ファーマシューティカルズ カンパニー リミテッド イコチニブリン酸塩の新規な多形及びその使用
WO2022022434A1 (zh) * 2020-07-27 2022-02-03 杭州和正医药有限公司 含托法替尼药学上可接受的盐的药物组合物、制剂及应用
WO2022166794A1 (zh) * 2021-02-02 2022-08-11 贝达药业股份有限公司 埃克替尼在非小细胞肺癌术后辅助治疗中的应用
CN116492293A (zh) * 2022-01-25 2023-07-28 杭州和正医药有限公司 一种含托法替尼的局部用药的药物组合物、制剂及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2630696A1 (en) * 2005-11-24 2007-05-31 Basf Se Keratin-binding effector molecules and method for the production thereof by coupling keratin-binding polypeptides with effector molecules that support carboxylic groups or sulfonic acid groups
FR2909284B1 (fr) * 2006-11-30 2012-09-21 Galderma Sa Nouvelles compositions sous forme d'onguent sans vaseline comprenant un derive de vitamine d et eventuellement un anti-inflammatoire steroidien
US8822482B2 (en) 2008-07-08 2014-09-02 Beta Pharma, Inc. Icotinib hydrochloride, synthesis, crystalline forms, pharmaceutical compositions, and uses thereof
GB201010954D0 (en) * 2010-06-29 2010-08-11 Edko Pazarlama Tanitim Ticaret Compositions
WO2012053007A1 (en) * 2010-10-21 2012-04-26 Cadila Healthcare Limited Topical pharmaceutical compositions containing nanodroplets for the treatment psoriasis

Also Published As

Publication number Publication date
RU2698796C2 (ru) 2019-08-30
RU2016118063A (ru) 2017-11-16
WO2015051763A1 (zh) 2015-04-16
CA2926874C (en) 2018-12-11
EP3056206A4 (en) 2017-07-05
AU2014334222B2 (en) 2017-03-09
US20190321369A1 (en) 2019-10-24
TWI630921B (zh) 2018-08-01
HK1213813A1 (zh) 2016-07-15
CA2926874A1 (en) 2015-04-16
IL245015A0 (en) 2016-05-31
AU2014334222A1 (en) 2016-05-05
TW201513894A (zh) 2015-04-16
EP3056206A1 (en) 2016-08-17
JP2016532659A (ja) 2016-10-20
NZ718802A (en) 2017-09-29
SG11201602826VA (en) 2016-05-30
US20160235757A1 (en) 2016-08-18
JP6463745B2 (ja) 2019-02-06

Similar Documents

Publication Publication Date Title
IL264413B (en) Preparations containing fibers obtained electrohydrodynamically for delivering specific doses of active substance to the skin or mucous membrane
SG10201808102WA (en) Bicyclic heterocycle compounds and their uses in therapy
BR112016000561B8 (pt) Compostos terapeuticamente ativos, uso dos mesmos, composição farmacêutica e uso da mesma
TW201613593A (en) Molecules for administration to ROS1 mutant cancer cells
PH12016500978A1 (en) Piperazine derivatives having multimodal activity against pain
MY167691A (en) A pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid
MX2015010185A (es) Composicion para uso cosmetico adecuada para producir un efecto de pigmentacion sobre el cabello.
BR112016021023A8 (pt) composições de corticosteroides tópicos
MX2016006604A (es) Derivados de piperidina con actividad multimodal contra el dolor.
MX2018000419A (es) Derivados de amida sustituida que tienen actividad multimodal contra el dolor.
MY165888A (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
MX2017006437A (es) Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor.
BR112016007627A2 (pt) composições farmacêuticas tópicas para a pele contendo icotinib e utilizações das mesmas
ECSP14010868A (es) Fenilimidazopirazoles sustituidos y su uso
HK1222337A1 (zh) 用於施加藥物活性成分或化妝品活性成分的局部組合物和載體
MX2018000262A (es) Usos terapeuticos de formulaciones de berberina.
CO2018011797A2 (es) Derivados de tetrahidropirano y tiopirano que tienen actividad multimodal contra el dolor
TR201908151T4 (tr) İzoindolin türevleri.
BR112016017496A2 (pt) Composição para acelerar a penetração através da pele, preparação para administração transdérmica e preparação de emplastro de pele
MX2015014905A (es) Compuestos de pirazino - [1,2-a] indol, su preparacion y su uso en medicamentos.
CO2018004803A2 (es) Compuestos oxa-diazaspiro que tienen actividad contra el dolor
MX2018004774A (es) Derivados de morfolina sustituidos que tienen actividad contra el dolor.
PH12015502420A1 (en) PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS
BR112014032850A2 (pt) combinações de princípios ativos, preparações cosméticas ou dermatológicas, e, uso de combinações de princípios ativos
MX2012006272A (es) Uso de la betanidina, isobetanidina y sus derivados para preparar un medicamento para el tratamiento de ateroscleosis.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2640 DE 10-08-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.